Anti-inflammatory effect and antihepatoma mechanism of carrimycin

Table 1 Key target genes of carrimycin in the treatment of liver cancer

Gene name	Degree	Betweenness centrality	Closeness
ALB	110	0.04074405	0.97413793
ESR1	102	0.02219136	0.91129032
EGFR	97	0.01545146	0.87596899
IGF1	95	0.01457077	0.86259542
HSP90AA1	93	0.02011442	0.84962406
CASP3	93	0.01307351	0.84962406
AR	91	0.01215915	0.83703704
SRC	90	0.01137002	0.83088235
PPARG	89	0.01582869	0.82481752
MAPK1	88	0.00943128	0.81884058
IL2	86	0.01154328	0.80714286
SOD2	84	0.01534439	0.79577465
MAPK14	84	0.00918383	0.79577465
NOS3	83	0.0095422	0.79020979
MMP9	83	0.00820256	0.79020979

ALB: Albumin; ESR1: Estrogen receptor 1; EGFR: Epidermal growth factor receptor; IGF: Insulin-like growth factor; HSP: Heat shock protein; CASP3: Recombinant caspase 3; AR: Androgen receptor; SRC: Sarcoma gene; PPARG: Peroxisome proliferator activated receptor gamma; MAPK1: Mitogen-activated protein kinase 1; IL: Interleukin; SOD: Superoxide dismutase; NOS: Nitric oxide synthase; MMP: Matrix metallo proteinase.

Table 2 Binding energy between carrimycin and the key target

Key target	Binding energy (kcal/mol)
ALB	-9.3
ESR1	-5.8
EGFR	-6.5
CASP3	-6.1
AR	-5.6
HSP90AA1	-5.0
IGF1	-5.1
MAPK1	-6.7
MAP2K1	-5.2
IL2	-5.8

ALB: Albumin; ESR1: Estrogen receptor 1; EGFR: Epidermal growth factor receptor; IGF: Insulin-like growth factor; HSP: Heat shock protein; CASP3: Recombinant caspase 3; AR: Androgen receptor; MAPK1: Mitogen-activated protein kinase 1; IL: Interleukin.